Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About

Johnson & Johnson is experiencing strong performance with stock up 28% YTD, driven by FDA clearance for its Ottava surgical robot, 64 consecutive years of dividend increases, and $100 billion revenue target. Most significantly, the company reached a proposed $5.5 billion settlement to resolve thousands of talc-related lawsuits, potentially eliminating a major legal risk. The company maintains resilience through diversified products and continues innovation with new drug approvals.